Maxwell (Max) Summerlin, M.D., is a board-certified pediatrician and clinical geneticist with additional fellowship training in medical biochemical genetics. His clinical and academic interests center on the diagnosis and management of inherited metabolic disorders, newborn screening, and the development and implementation of emerging therapies for rare genetic diseases.

Dr. Summerlin has participated as a sub-investigator in clinical trials involving phenylketonuria, GLUT1 deficiency syndrome, and gene therapy for inherited metabolic disorders. His scholarly work includes research on ornithine aminotransferase deficiency, fatty acid oxidation disorders, rhabdomyolysis, metabolic liver disease, and uncommon complications of inherited metabolic conditions. He is particularly interested in translating advances in biochemical genetics and rare-disease therapeutics into practical improvements in clinical care.

Dr. Summerlin is also interested in medical education and the role of digital and social media in making genetics education more accessible, engaging, and clinically relevant. He completed his combined Pediatrics and Medical Genetics residency at Children’s Hospital Colorado, where he served as Chief Resident for Medical Genetics, and completed his Medical Biochemical Genetics fellowship at Oregon Health & Science University.